DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This is randomized, active-Controlled, double-blind clinical study is designed to evaluate
the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL
[MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1)
infection. It is hypothesized that DOR/ISL is non-inferior to
bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage
of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48.